Corporate Banner
Satellite Banner
Medicinal Chemistry
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Pfizer and Renovis Extend Research Collaboration to Identify Small Molecule VR1 Antagonists

Published: Tuesday, April 10, 2007
Last Updated: Tuesday, April 10, 2007
Bookmark and Share
Pfizer will continue to fund the research and preclinical development efforts at Renovis through June 30, 2008, to advance small molecule VR1 antagonists toward clinical development.

Renovis, Inc. has announced an agreement with Pfizer Inc. to extend the term of the companies' worldwide collaboration to research, develop and commercialize small molecules that target the vanilloid receptor, VR1. This extension provides Renovis with additional research funding through June 30, 2008 and reflects the goal of Pfizer and Renovis to advance multiple, small molecule VR1 antagonists toward clinical development.

The VR1 receptor is a member of a related group of ion channel proteins known as the transient receptor potential (TRP) family that mediate and influence cell signaling. Inhibitors of VR1 are predicted to be useful in the treatment of pain, urinary incontinence and other diseases and disorders.

"We partnered our VR1 program with Pfizer in June 2005 at a preclinical stage because we believed that safe and effective antagonists of VR1 could potentially address major medical needs in multiple therapeutic areas and we wanted to work with a partner capable of aggressively pursuing this broad potential with us," stated Corey S. Goodman, Ph.D., President and Chief Executive Officer of Renovis.

"Since then, the collaboration has produced its first advanced candidate, which we expect to enter human testing in 2007, as well as several other small molecule VR1 antagonists that we hope to advance into IND-enabling studies and clinical development with Pfizer during the term of this extension," Goodman continued.

"VR1 antagonists represent an enormous opportunity to help large numbers of patients who are poorly served by existing therapies," added Michael G. Kelly, Ph.D., Senior Vice President of Research and Development. "We are strongly committed to doing all that we can with Pfizer to deliver on this promise."

Under the terms of the extension, Pfizer will continue to fund all aspects of the collaboration including the research and preclinical development efforts at Renovis through June 30, 2008.

Other terms of the collaboration and licensing agreements between Pfizer and Renovis have not been changed.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Pfizer to Acquire Hospira for $17B
Companies have into a definitive merger agreement under which Pfizer will acquire Hospira for $90 a share in cash for a total enterprise value of approximately $17 billion.
Thursday, February 05, 2015
Pfizer to Acquire InnoPharma
Under the terms of the agreement, Pfizer will acquire InnoPharma for an upfront cash payment of $225 million, with up to $135 million of contingent milestone payments.
Wednesday, July 16, 2014
Pfizer Confirms Interest in AstraZeneca
Pfizer submitted a preliminary, non-binding indication of interest to the board of directors of AZ in January 2014 regarding a possible merger transaction.
Monday, April 28, 2014
Pfizer Announces Resolutions with DOJ and SEC Related to Certain International Operations
U.S. agencies praise Company’s cooperation and compliance program.
Thursday, August 09, 2012
Pfizer Joins Open-Access Medicinal Chemistry Public-Private Collaboration
Company joins the SGC-led public-private collaboration to generate small molecule inhibitors for proteins involved in epigenetic signalling.
Tuesday, June 15, 2010
Pfizer, Washington University Announce Collaboration
Pfizer will provide Washington University scientists access to research data on a large array of its pharmaceutical candidates for indications discovery.
Thursday, May 20, 2010
Pfizer Receives FDA Approval for Geodon® Capsules for the Adjunctive Maintenance Treatment of Bipolar Disorder in Adults
Data show Geodon used as an adjunct to Lithium or Valproate Is effective in the maintenance treatment of Bipolar I disorder.
Monday, November 23, 2009
Pfizer Announces Partnership with Shanghai Institutes for Biological Sciences for Drug Discovery Activities
Pfizer will provide US$500,000 each year over three years to fund health-related fundamental research projects at SIBS.
Thursday, July 30, 2009
Pfizer Launches Global Regenerative Medicine Research Unit
The new independent research unit will provide new generation of regenerative medicines for major medical needs.
Monday, November 17, 2008
Pfizer Report Demonstrates Value of Conducting Virtual Studies of Drug-Drug Interactions
Scientists have used the Simcyp Simulator to predict the extent of drug-drug interactions for maraviroc, which is used in the treatment of HIV.
Thursday, June 12, 2008
Scientific News
Toxin from Salmonid Fish has Potential to Treat Cancer
Researchers from the University of Freiburg decode molecular mechanism of fish pathogen.
New Diabetes Drug has Unexpected Side Effect
A type of drug used to treat diabetes may reduce the risk of developing Parkinson’s disease, according to new research.
Researchers Develop Vaccine that Protects Primates Against Ebola
A collaborative team from The University of Texas Medical Branch at Galveston and the National Institutes of Health have developed an inhalable vaccine that protects primates against Ebola.
Cannabis May Be Used to Treat Fractures
TAU researcher finds non-psychotropic compound in marijuana can help heal bone fissures.
A Novel Drug to FIght Malaria
An international team of scientists has announced that a new compound to fight malaria is ready for human trials.
New Cell Structure Finding Might Lead to Novel Cancer Therapies
University of Warwick scientists in the U.K. say they have discovered a cell structure which could help researchers understand why some cancers develop.
Creating More Potent Vaccines
Yale researchers uncovered a new role for a type of immune cell, known as regulatory T cells, in promoting long-term immunity.
Potential Therapeutic for Blinding Eye Disease
NIH research points to microglia as potential therapeutic target in retinitis pigmentosa.
Potential New Class of Cancer Drugs
Scientists have found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.
Global Search for Next Antibiotic
University of Queensland researchers have launched a global search to discover antibiotics capable of combating superbug bacteria that are resistant to current antibiotics.
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!